Skip to main content
Evidence Snapshot

Glycogen synthase kinase-3 beta

CHEMBL262 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:14:12Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL262
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glycogen synthase kinase-3 beta as ChEMBL target CHEMBL262, mapped to UniProt P49841. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glycogen synthase kinase-3 beta
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL262
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P49841
Glycogen synthase kinase-3 beta
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Glycogen synthase kinase-3 beta matters

As of 2026-09-13

Glycogen synthase kinase-3 beta is reviewed as Glycogen synthase kinase-3 beta (UniProt P49841); Glycogen synthase kinase-3 beta shows clinical signal disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 10 approved drugs, 11262 compounds, and 1695 assays, with lead potency reaching pChEMBL 10.9.

Disease context
Alzheimer disease

Glycogen synthase kinase-3 beta shows clinical signal disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include TIDEGLUSIB.

Start review with Alzheimer disease because it currently carries clinical signal support. Linked drugs include TIDEGLUSIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 10 approved drugs, 11262 compounds, and 1695 assays for this target. The dominant activity type is IC50. CHEMBL2386094 is the current potency anchor at pChEMBL 10.9.

Use CHEMBL2386094 as the tractability anchor when discussing potency (pChEMBL 10.9).

Activity source · ChEMBL 36 via Core Engine
10 approved pChEMBL 10.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Glycogen synthase kinase-3 beta matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P49841, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Alzheimer disease is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

11262
Total Compounds
1695
Total Assays
10
Approved Drugs
IC50: 5016.0, KI: 1829.0, EC50: 2934.0, KD: 483.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2386094
 10.9 IC50 —
No preferred name
CHEMBL4647659
 10.3 Kd —
No preferred name
CHEMBL1232189
 10.3 Kd —
No preferred name
CHEMBL1082152
 10.3 Kd —
No preferred name
CHEMBL5290966
 10.2 IC50 —

Approved Drugs

Structure Compound First Approval
ENCORAFENIB
CHEMBL3301612
 2018
ABEMACICLIB
CHEMBL3301610
 2017
NINTEDANIB
CHEMBL502835
 2014
EPALRESTAT
CHEMBL56337
 1992
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:14:12Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL262